What is Keystone Bioanalytical?
Keystone Bioanalytical operates at the intersection of precision science and industrial-scale laboratory services. The company specializes in quantitative LC/MS/MS method development, validation, and comprehensive sample analysis. By maintaining a rigorous focus on high-throughput analytical workflows, Keystone Bioanalytical serves as an essential partner for organizations navigating complex drug development pipelines. Their commitment to technical excellence and regulatory compliance positions them as a high-authority entity in the bioanalytical landscape, providing the data integrity required for global clinical trials and research initiatives.
How much funding has Keystone Bioanalytical raised?
Keystone Bioanalytical has raised a total of $699K across 2 funding rounds:
Debt
$350K
Debt
$349K
Debt (2020): $350K with participation from PPP
Debt (2021): $349K led by PPP
Key Investors in Keystone Bioanalytical
PPP
Public-Private Partnership
What's next for Keystone Bioanalytical?
With the recent influx of capital, Keystone Bioanalytical is well-positioned to scale its enterprise-level operations and enhance its technological infrastructure. The strategic deployment of these funds will likely focus on expanding laboratory capacity, integrating advanced mass spectrometry instrumentation, and accelerating the development of proprietary analytical methods. As the demand for outsourced bioanalytical services continues to rise, the company is poised to leverage this financial backing to capture greater market share, optimize operational efficiencies, and maintain its competitive edge in providing high-fidelity analytical support to its global client base.
See full Keystone Bioanalytical company page
